An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Blood

Volumn 123, Issue 6, 2014, Pages 837-842

  Zhou, Zheng ^a   Sehn, Laurie H ^b   Rademaker, Alfred W ^a   Gordon, Leo I ^a   LaCasce, Ann S ^c   Crosby Thompson, Allison ^c   Vanderplas, Ann ^d   Zelenetz, Andrew D ^e   Abel, Gregory A ^c   Rodriguez, Maria A ^f   Nademanee, Auayporn ^d   Kaminski, Mark S ^g   Czuczman, Myron S ^h   Millenson, Michael ⁱ   Niland, Joyce ^d   Gascoyne, Randy D ^b   Connors, Joseph M ^b   Friedberg, Jonathan W ^j   Winter, Jane N ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; VALIDATION STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROGRAM DEVELOPMENT;

EID: 84894080724     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-524108     Document Type: Article

References (28)

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4): 235-242.
3. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(19):3121-3127.
4. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD201 B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14): 2373-2380.
5. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5): 1857-1861.
6. Cox MC, Nofroni I, Ruco L, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008;49(9):1745-1751.
7. Advani RH, Chen H, Habermann TM, et al; Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): Consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010;151(2): 143-151.
8. Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood. 2011;118(5):1350-1358.
9. Lenz G, Wright G, Dave SS, et al; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-2323.
10. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828-1837.
11. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):995-1007.
12. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200-207.
13. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74.
14. Hong F, Kahl BS, Gray R. Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma. Blood. 2013;121(1):156-158.
15. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: A study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117(26):7070-7078.
16. Kho ME, Lepisto EM, Niland JC, Friedberg JW, Lacasce AS, Weeks JC. Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database. Cancer. 2008; 113(11):3209-3212.
17. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL Database. Blood. 2012;119(9):2093-2099.
18. Harrell FEJ. General Aspects of Fitting Regression Models. Regression Modeling Strategies: With applications to Linear models, Logistic regression, and survival analysis. New York: Springer-Verlag; 2001:19-26.
19. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrics. 1995;51(4):1469-1482.
20. Kremers WK. Concordance for survival time data: Fixed and time-dependent covariates and possible ties in predictor and time. Technical Report Series No. 80. Rochester, MN: Mayo Foundation; 2007.
21. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed. Hoboken: John Wiley & Sons; 2003
22. Rosenwald A, Wright G, Chan WC, et al; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25): 1937-1947.
23. Wright G, Tan B, Rosenwald A, Hurt EH,Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100(17):9991-9996.
24. Canellos GP. What constitutes "improved prognosis"? J Clin Oncol. 2008;26(12): 1913-1914.
25. Müller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119(14): 3276-3284.
26. Klapper W, Kreuz M, Kohler CW, et al; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119(8):1882-1887.
27. Gordon LI, Andersen J, Colgan J, et al. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Cancer. 1995;75(3):865-873.
28. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.